Fluzone QIV HD is under clinical development by Sanofi and currently in Phase II for Unspecified Influenza Virus Infections.

While the first combination pairs the Fluzone HD vaccine with Novavax’s COVID-19 vaccine, the second combines Sanofi’s Flubok influenza vaccine with the NVAX COVID-19 vaccine.

The first combination vaccine candidate (NCT06695117) consists of the influenza protein-based trivalent vaccine Fluzone High-Dose combined with the adjuvanted recombinant Novavax Covid-19 vaccine. The ...

is comprised of the influenza protein-based trivalent vaccine Fluzone High-Dose combined with the adjuvanted recombinant Novavax COVID-19 vaccine. The second candidate (NCT06695130) includes the ...

The novel vaccines are currently being investigated in 2 separate parallel, randomized, modified double-blind, multiarm phase 1/2 clinical studies (Fluzone High-Dose/Novavax; ClinicalTrials.gov ...

combines SNY’s influenza protein-based trivalent vaccine, Fluzone High-Dose and Novavax’s NVAX adjuvanted recombinant Novavax COVID-19 vaccine, NVXC19. NCT06695130, the second vaccine candidat ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

Both experimental vaccines will utilize the company’s proprietary ... Novavax’s own COVID-19 vaccine and influenza vaccines Fluzone HD and Fluad, marketed by Sanofi SNY and CSL Seqirus ...